Tin tức & Cập nhật

A systematic review and meta-analysis conducted by researchers from Singapore demonstrates an association between treatment with sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, and the risk of Alzheimer's disease (AD).

Blood-based biomarkers (BBBs) may potentially aid earlier detection of Alzheimer’s disease (AD) following a recent revision of diagnostic criteria supporting core biomarker–based diagnosis. Initial local experience with lecanemab, a disease-modifying therapy (DMT) for patients with mild cognitive impairment or mild dementia due to AD, was shared at Advances in Medicine (AIM) 2025.